Admission serum albumin level was an independent predictor of angiographic no-reflow after primary percutaneous coronary intervention (OR 0.114; 95% CI 0.032-0.405; P=0.001).
Observational (n=536)
Odds Ratio: 0.114 (95% CI 0.032–0.405)
p-value: p=0.001
Low serum albumin (SA) levels are associated with increased cardiovascular mortality. We investigated whether baseline SA levels are associated with no-reflow following primary percutaneous coronary intervention (pPCI). A total of 536 patients (aged 60 ± 13 years; 74% men) who underwent pPCI were enrolled. The patients were divided into 2 groups: no-reflow and normal-reflow. No-reflow was defined as thrombolysis in myocardial infarction ≤2 flow. Admission SA levels were significantly lower in the no-reflow group than in the normal-reflow group (3.55 ± 0.44 vs 4.01 ± 0.32 mg/dL, P < .001). Also, high-sensitivity C-reactive protein (hsCRP), creatinine, creatine kinase myocardial band isoenzyme, and troponin T were significantly higher while hemoglobin and left ventricular ejection fraction (LVEF) were significantly lower in the no-reflow group. In multivariate analysis, SA level remained an independent predictor of angiographic no-reflow (odds ratio 0.114, 95% confidence interval 0.032-0.405, P = .001) together with LVEF, hsCRP, and baseline culprit artery patency. Admission SA level was an independent predictor of no-reflow after pPCI.
Kurtul et al. (Wed,) conducted a observational in ST-Segment Elevation Myocardial Infarction (n=536). Serum albumin levels on admission was evaluated on Angiographic no-reflow (thrombolysis in myocardial infarction ≤2 flow) (OR 0.114, 95% CI 0.032-0.405, p=0.001). Admission serum albumin level was an independent predictor of angiographic no-reflow after primary percutaneous coronary intervention (OR 0.114; 95% CI 0.032-0.405; P=0.001).